ScholarDeck

Case-controlJournal of thrombosis and haemostasis : JTH · 2026

Plasma levels of adiponectin and risk of future incident venous thromboembolism.

Asbjørn L Onsaker, Astrid van Hylckama Vlieg, Thor Ueland … Vânia M Morelli

Read paper

Internal MedicineCase-control

Higher plasma adiponectin levels associated with lower risk of first venous thromboembolism

Plasma levels of adiponectin and risk of future incident venous thromboembolism.

Asbjørn L Onsaker … Vânia M Morelli

Journal of thrombosis and haemostasis : JTH · 2026

Background

Adiponectin, a hormone-like protein primarily secreted by adipocytes, is typically decreased in obesity.

Purpose

To investigate the association between plasma adiponectin levels and risk of future first lifetime VTE.

Methods

A population-based nested case-control study, including 381 VTE cases and 772 age-and sex-matched controls, was derived from the Tromsø4 survey (1994/95-2007).

n = 381 VTE cases and 772 age-and

Results

high adiponectin, lower future clot risk

OR 0.69 (95% CI 0.48 to 0.99)

null 1

0.48

0.99

CI excludes the null - significant

More results

Q1 (reference) in age- and sex-adjusted analysis for the entire study period.

Q1.

The additional adjustment for body mass index and C-reactive protein had minor impact on risk estimates.

“

Conclusion

Our results suggest that high plasma adiponectin levels are associated with decreased risk of future first lifetime VTE, particularly shortly after cohort inclusion, and that adiponectin might play a role in the pathogenesis of VTE.

Post

Plasma levels of adiponectin and risk of future incident venous thromboembolism.

Higher plasma adiponectin levels associated with lower risk of first venous thromboembolism

Related papers